Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,0798€
Last updated
29/11/2025 - 04:43
-1,60%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and
Presentations
Financial
Results
Governance
Mauna Kea Technologies Shareholder Webinar (English subtitles available)
No results found.
MKT – Shareholder Webinar – Nov 18 2025
No results found.
Voting Rights Information – October 2025
No results found.
Corporate Presentation October 2025
No results found.
Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates
No results found.
News
Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise
Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
GILBERT DUPONT
Guillaume Cuvillier
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France